iBio (IBIO) Change in Accured Expenses (2010 - 2026)

iBio (IBIO) has reported Change in Accured Expenses for 17 consecutive years, with $415000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 72.92% year-over-year to $415000.0; the TTM figure through Mar 2026 stood at $242000.0 (up 112.51% YoY), while the FY2025 annual figure was -$758000.0, up 56.08% from the prior year.
• Change in Accured Expenses slipped to $415000.0 in Q1 2026 per IBIO's latest filing, from $567000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.4 million in Q4 2022 and bottomed at -$1.3 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$66000.0 across 5 years, with a median of $8000.0 in 2024.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses slumped 1407.29% — and 2025, when it surged 6987.5%.
• iBio's Change in Accured Expenses stood at $2.4 million in 2022, then plunged by 100.29% to -$7000.0 in 2023, then soared by 214.29% to $8000.0 in 2024, then soared by 6987.5% to $567000.0 in 2025, then retreated by 26.81% to $415000.0 in 2026.
• Business Quant data shows IBIO's Change in Accured Expenses at $415000.0 in Q1 2026, $567000.0 in Q4 2025, and -$686000.0 in Q3 2025.